Managing diabetes in diabetic patients with COVID: where do we start from?

Aims COVID-19 has and still is sweeping away the national health systems worldwide. In this review, we sought to determine the evidence base proofs on the antidiabetic treatment capable to reduce the risk of COVID-19-related mortality. Methods We have performed a systematic search of published articles using PubMed, and EMBASE from March 2020 to March 31st, 2021. We excluded editorials, commentary, letters to the editor, reviews, and studies that did not have mortality as an outcome. For metformin and insulin only, we performed a meta-analysis using Cochrane RevMan 5.2. Results Among antidiabetic drugs, metformin was the only drug associated with a reduced risk of mortality. Conversely, insulin appears associated with an increased risk. The other classes of drugs were neutral. Conclusions The totality of articles reports retrospective data strongly affected by channeling bias so that most of the existing results on each class of drugs are driven by the phenotype of patients likely to receive that specific drug by prescription.

Automated summary

The study found that metformin may reduce the risk of COVID-19-related mortality, while insulin may increase the risk. Other classes of antidiabetic drugs were neutral. The results of the study are influenced by channeling bias.